
📖 🔥 New online #firmonertinib in EGFR #PACC-mut NSCLC. @Cancer_Cell 👉 Firmonertinib has a trifluoroethoxy group, which enhances its potency against EGFR PACC mutation 👉 68% response rate with firmonertinib 240 mg daily. Median progression-free survival of 16.0 months at 240 mg. 👉 47% intracranial response rate among patients with baseline brain metastases. @EGFRResisters @Exon20Group @lungoncdoc @riess_md
Results from the Phase 1b FURTHER trial found a targeted therapy that achieved achieved durable antitumor activity for patients with EGFR PACC-mutated non-small cell lung cancer. @LeXiuning #EndCancer spr.ly/6014BHMzuy
View quoted post ↗









































